Dr. Yang Shao


Founder of Genesseq, CEO of Geneseeq China

Early in his career, Dr. Yang Shao was inspired by the rapid momentum of advancements in cancer genomics. He anticipated the tremendous power of precision medicine in the treatment of cancer. In 2008, as a PhD student at the University of Toronto, Dr. Shao and several of his colleagues self-funded their first R&D Lab to explore the potential of precision medicine technologies to treat cancer. In 2012, when Dr. Shao was 25 years old, they established Geneseeq’s North American Headquarters at the MaRS Centre in Toronto, Canada.

Dr. Shao firmly believes that science drives innovations. His innovative ideas helped his team and company to always stay ahead in the field of Next-Generation Sequencing (NGS). Geneseeq has grown to be one of the world’s leading companies in cancer genomics, with over 800 employees. Dr. Shao owns 9  NGS-related patents and has published numerous clinical research papers in peer-reviewed international journals. He actively collaborates and supports cancer research at research institutes and universities both in Canada and China. He is currently a board member and distinguished Professor at Nanjing Medical University. In addition, Dr. Shao is actively involved in compiling the first consensus of NGS-based genetic testing guidelines in China, as well as promoting the standardization of the NGS test field for improved patient care.

Dr. Shao has received numerous awards and recognitions for his work. In 2017, he was named a recipient of Forbes’ 30 Under 30 in the Asia Healthcare & Science category, and has won Gold in the Young Enterpreneurs category at the Canada-China Business Council (CCBC).